The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Antiretroviral preexposure prophylaxis is a promising approach for preventing human immunodeficiency virus type 1 (HIV-1) infection in heterosexual populations. ⋯ Oral TDF and TDF-FTC both protect against HIV-1 infection in heterosexual men and women. (Funded by the Bill and Melinda Gates Foundation; Partners PrEP ClinicalTrials.gov number, NCT00557245.).
-
Randomized Controlled Trial Multicenter Study
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Preexposure prophylaxis with antiretroviral agents has been shown to reduce the transmission of human immunodeficiency virus (HIV) among men who have sex with men; however, the efficacy among heterosexuals is uncertain. ⋯ Daily TDF-FTC prophylaxis prevented HIV infection in sexually active heterosexual adults. The long-term safety of daily TDF-FTC prophylaxis, including the effect on bone mineral density, remains unknown. (Funded by the Centers for Disease Control and Prevention and the National Institutes of Health; TDF2 ClinicalTrials.gov number, NCT00448669.).
-
Editorial Comment
Preexposure prophylaxis for HIV--where do we go from here?